Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

EYEG vs BNTC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EYEG Captures Overall Composite Edge (55.0 HOLD vs 40.8 SELL), While BNTC Leads 3–1 on Growth & Valuation Pillars

EYEG Overall Winner 6-Pillar Tally: EYEG 1 – 3 BNTC (2 Tie) Matrix Metrics: EYEG 3 – 5 BNTC

As of Nov 20, 2026, EYEG (EYEG) captures the overall head-to-head institutional edge over Benitec Biopharma Inc. (BNTC) on higher Unified Composite conviction (55.0/100 HOLD vs. 40.8/100 SELL) after splitting the core matrix 3–5 (led by Options & Positioning), while BNTC wins 3–1 across the 6-pillar growth and valuation breakdown. EYEG trades at $33.73 (N/M Forward P/E, N/A operating margin) versus BNTC at $7.92 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: EYEG earns the overall head-to-head edge with a stronger Unified Composite Score (55.0/100 HOLD vs. BNTC 40.8/100 SELL) and 0.13β · 5% Vol risk profile, whereas BNTC leads top-line expansion (+12.5% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: EYEG trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 51.7); meanwhile BNTC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EYEG vs BNTC
EYEG US Equity Head-to-Head Winner
EYEG
Institutional Equity
$33.73
+0.48% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.13β · 5% Vol
Unified Composite Score
55.0 / 100 HOLD
Tech 73.0 Fund 61.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 51.7 · SMA20: $33.74 · SMA50: $33.69
BNTC NASDAQ
Benitec Biopharma Inc. Common Stock
Pharmaceutical Preparations
$7.92
-2.76% 1D
Market Cap $294.0M
TTM Revenue $7,000
Forward P/E N/M
Beta / 30D Vol 1.52β · 70% Vol
Unified Composite Score
40.8 / 100 SELL
Tech 28.0 Fund 50.0 Flow 63.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -14.5%), weak momentum, RSI 38
RSI-14: 38.1 · SMA20: $8.79 · SMA50: $9.25

6-Pillar Scorecard Institutional Category Breakdown (EYEG 1 – 3 BNTC)

Columns: Metric · EYEG · BNTC
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale BNTC
Revenue Growth (YoY) N/A +12.5%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $7,000
Market Cap N/A $294.0M
3. Profitability & Quality BNTC
Gross Margin N/A 0.0%
Operating Margin N/A 0.0%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A -37.6%
4. Balance Sheet & Cash Flow BNTC
Cash Generation (TTM) N/A -$17M
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $176M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EYEG
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 75.2% (6th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EYEG (3) vs BNTC (5)
Institutional Metric EYEG BNTC Criterion Row Edge
Market Capitalization
Scale
N/A $294.0M Larger Scale BNTC
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A +12.5% Higher Growth BNTC
Operating Margin (TTM)
Profitability
N/A 0.0% Higher Margin BNTC
Net Profit Margin
Profitability
N/A 0.0% Higher Margin BNTC
Return on Equity (ROE)
Capital Efficiency
N/A -37.6% Higher ROE BNTC
52-Week Range Position
Momentum
15% ($33–$36) 3% ($8–$14) Stronger Trend EYEG
Beta / 30D Volatility
Risk Regime
0.13β · 5% Vol 1.52β · 70% Vol Lower Realized Risk EYEG
Unified Institutional Score
Composite Signal
55.0 / 100 (HOLD) 40.8 / 100 (SELL) Higher Composite EYEG
Trailing 12M Revenue (USD)
Operating Scale
N/A $7,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 0.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$17M ($176M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EYEG +7.3 pp
EYEG: +0.42% · BNTC: -6.88%
3M Horizon EYEG +39.08 pp
EYEG: -2.2% · BNTC: -41.28%
6M Horizon EYEG +26.43 pp
EYEG: -3.9% · BNTC: -30.33%
1Y Horizon EYEG +33.71 pp
EYEG: -5.87% · BNTC: -39.58%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EYEG vs BNTC. Trailing 12-month operating profitability (EYEG N/A vs BNTC 0.0%) and valuation multiples (EYEG N/M vs BNTC N/M Forward P/E) are benchmarked directly in Pillar 4 below.

EYEG ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
BNTC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$7,000
Gross Margin0.0%
Op. Margin0.0%
ROE / Fwd P/E-37.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EYEG UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact EYEG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BNTC BREAKDOWN
151d in phase · OBV DISTRIBUTION
Current IV 75.2%
IV Percentile 6th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact BNTC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EYEG Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BNTC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $294.0M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ EYEG vs BNTC Key Questions & Quantitative Answers

As of Nov 20, 2026, EYEG (EYEG) captures the overall head-to-head institutional edge over Benitec Biopharma Inc. (BNTC) on higher Unified Composite conviction (55.0/100 HOLD vs. 40.8/100 SELL) after splitting the core matrix 3–5 (led by Options & Positioning), while BNTC wins 3–1 across the 6-pillar growth and valuation breakdown. EYEG trades at $33.73 (N/M Forward P/E, N/A operating margin) versus BNTC at $7.92 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: EYEG earns the overall head-to-head edge with a stronger Unified Composite Score (55.0/100 HOLD vs. BNTC 40.8/100 SELL) and 0.13β · 5% Vol risk profile, whereas BNTC leads top-line expansion (+12.5% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: EYEG trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 51.7); meanwhile BNTC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BNTC leads the Growth & Scale pillar: EYEG posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with BNTC at +12.5% YoY revenue growth and +0.0% YoY earnings growth on $7,000 TTM revenue (0.0% gross margin, 0.0% operating margin). On trailing 12-month operating scale, EYEG generates N/A in USD-normalized revenue versus $7,000 for BNTC. In operating R&D and SG&A reinvestment, EYEG deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BNTC.

EYEG and BNTC trade at balanced relative valuation multiples. EYEG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas BNTC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EYEG (N/A ROE) versus BNTC (-37.6% ROE) capital efficiency.

In options market volatility and institutional positioning, EYEG carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.13β · 5% Vol realized risk). By comparison, BNTC carries 75.2% implied volatility (6th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.52β · 70% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.